Search
RGX-111
go.drugbank.com/drugs/DB17632InvestigationalRGX-111 is an adeno-associated virus vector AAV9 designed to deliver the α-L-iduronidase (IDUA) gene. … Developed by REGENXBIO Inc., it was investigated for the treatment of mucopolysaccharidosis Type I (MPS I).[L46666]
Metribolone
go.drugbank.com/drugs/DB02998ExperimentalIt binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.
3-methyl-benzene-1,2-diol
go.drugbank.com/drugs/DB03454ExperimentalThis compound belongs to the catechols. These are compounds containing a 1,2-benzenediol moeity. 3-methyl-benzene-1,2-diol targets the protein biphenyl-2,3-diol 1,2-dioxygenase.
LAX-101
go.drugbank.com/drugs/DB05301InvestigationalThe molecules of EPA found in LAX-101 are identical to the molecules of EPA found in fish oil food supplements. … LAX-101 treats hungtington’s disease, not just the symptoms but the disease itself. The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical.
Meglutol
go.drugbank.com/drugs/DB04377Experimentalis the rate limiting enzyme in the biosynthesis of cholesterol. … It acts by interfering with the enzymatic steps involved in the conversion of acetate to hydroxymethylglutaryl coenzyme A as well as inhibiting the activity of HYDROXYMETHYLGLUTARYL COA REDUCTASES which
Altretamine
go.drugbank.com/drugs/DB00488ApprovedWithdrawnAn alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.
INCB7839
go.drugbank.com/drugs/DB05033InvestigationalINCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways.
Alisertib
go.drugbank.com/drugs/DB05220InvestigationalAlisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.
MYR-101
go.drugbank.com/drugs/DB17075InvestigationalIt is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase enzyme (ASPA). … [L43567] The FDA has granted MYR-101 Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for the treatment of patients with Canavan disease.[L43572]
Pipequaline
go.drugbank.com/drugs/DB13991ExperimentalPipequaline has a similar pharmacological profile to the reported for the benzodiazepines. … Due to these differences, this drug is classified as a nonbenzodiazepine anxiolytic.